Over 150 clinical papers have subsequently confirmed that high CIP2A levels are associated with adverse histology and/or poor response to treatment in over 20 different cancer histologies [20,21,22,23,24,25,26], including AML [17]. This evidence concerns the gene CIP2A and acute myeloid leukemia.